Four different regimens of farnesyltransferase inhibitor tipifarnib in older, untreated acute myeloid leukemia patients: North American Intergroup Phase II study SWOG S0432 Journal Article
| Authors: | Erba, H. P.; Othus, M.; Walter, R. B.; Kirschbaum, M. H.; Tallman, M. S.; Larson, R. A.; Slovak, M. L.; Kopecky, K. J.; Gundacker, H. M.; Appelbaum, F. R. |
| Article Title: | Four different regimens of farnesyltransferase inhibitor tipifarnib in older, untreated acute myeloid leukemia patients: North American Intergroup Phase II study SWOG S0432 |
| Abstract: | We report on 348 patients. ≥. 70 years (median age 78 years) with acute myeloid leukemia (>50% with secondary AML) randomized to receive either 600. mg or 300. mg of tipifarnib orally twice daily on days 1-21 or days 1-7 and 15-21, repeated every 28 days (4 treatment regimens). Responses were seen in all regimens, with overall response rate (CR. +. CRi. +. PR) highest (20%) among patients receiving tipifarnib 300. mg twice daily on days 1-21. Toxicities were acceptable. Unless predictors of response to tipifarnib are identified, further study as a single agent in this population is unwarranted. © 2013 Elsevier Ltd. |
| Keywords: | tipifarnib; older; acute myeloid leukemia; untreated; farnesyltransferase inhibitor |
| Journal Title: | Leukemia Research |
| Volume: | 38 |
| Issue: | 3 |
| ISSN: | 0145-2126 |
| Publisher: | Elsevier Ltd |
| Date Published: | 2014-03-01 |
| Start Page: | 329 |
| End Page: | 333 |
| Language: | English |
| DOI: | 10.1016/j.leukres.2013.12.001 |
| PROVIDER: | scopus |
| PUBMED: | 24411921 |
| PMCID: | PMC4247790 |
| DOI/URL: | |
| Notes: | Export Date: 2 April 2014 -- CODEN: LERED -- Source: Scopus |
